Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 476 publications
Post-HCT gilteritinib outweighs conditioning in NPM1m FLT3-ITD AML.
Journal: Blood advances
Published: October 16, 2025
Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.
Journal: Leukemia & lymphoma
Published: October 03, 2025
Rational design of next-generation FLT3 inhibitors in acute myeloid leukemia: From laboratory to clinics.
Journal: European journal of medicinal chemistry
Published: August 19, 2025
Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML.
Journal: Current treatment options in oncology
Published: July 30, 2025
A Case of Acute Myeloid Leukemia with an FMS-like Tyrosine Kinase 3-tyrosine Kinase Domain Mutation Developing Gilteritinib-induced Differentiation Syndrome.
Journal: Internal medicine (Tokyo, Japan)
Published: July 30, 2025
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.
Journal: bioRxiv : the preprint server for biology
Published: July 15, 2025
Successful allogeneic hematopoietic stem cell transplantation for AML with pulmonary mucormycosis under isavuconazole.
Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: June 25, 2025
Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation.
Journal: Hematology (Amsterdam, Netherlands)
Published: June 17, 2025
Synergy Between second-generation FLT3 inhibitors and the ERK1/2 inhibitor Ulixertinib in FLT3-ITD-mutated acute myeloid leukemia (AML) cells.
Journal: Medical oncology (Northwood, London, England)
Published: June 03, 2025
Preclinical Prediction of Resistance Mutations and Proposal of Sequential Treatment Strategies for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors.
Journal: Pharmaceutical research
Published: May 30, 2025
Drug-Drug Interaction Liabilities with BTK Inhibitor TL-895.
Journal: Cancer research communications
Published: May 19, 2025
Last Updated: 10/31/2025